RMP1-14

Introduction...

A groundbreaking study by researchers at Princeton University has revealed a promising strategy to enhance the efficacy of cancer immunotherapy by supplementing one-carbon (1C) units, essential building blocks for nucleotide synthesis. The findings, recently published as a preprint on bioRxiv, demonstrate that elevating circulating levels of formate, a key 1C unit donor, can significantly improve the response to ...

Introduction ...

Introduction                                     

In advancing cancer immunotherapy, antibodies against PD-1 have become a breakthrough and opened a new door for severely affected cancer patients. Nevertheless, the results of preclinical studies have faced various obstacles in transforming into successful clinical...

Introduction

As...

...

Introduction

The...

Immune checkpoint inhibitors have revolutionized cancer treatment, but response rates remain unsatisfactory in many tumor types. This highlights the need for complementary immunotherapeutic approaches targeting novel pathways beyond PD-1/PD-L1. CD39 has emerged as an exciting inhibitory target – this ectoenzyme generates immunosuppressive adenosine within the tumor microenvironment. Encouragingly, latest research indicates that neutralizing CD39 with...